Drugs for HER-2-positive Breast Cancer: Milestones in Drug Therapy
Editat de Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas W. Grunten Limba Engleză Paperback – 25 feb 2013
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1027.37 lei 6-8 săpt. | |
Springer – 25 feb 2013 | 1027.37 lei 6-8 săpt. | |
Hardback (1) | 1031.87 lei 6-8 săpt. | |
Springer – 7 ian 2011 | 1031.87 lei 6-8 săpt. |
Din seria Milestones in Drug Therapy
- 5% Preț: 1335.08 lei
- 5% Preț: 840.04 lei
- 5% Preț: 352.33 lei
- 5% Preț: 346.30 lei
- 5% Preț: 673.98 lei
- 5% Preț: 683.20 lei
- 5% Preț: 614.47 lei
- 5% Preț: 1044.69 lei
- 5% Preț: 1332.81 lei
- 5% Preț: 345.42 lei
- 5% Preț: 667.35 lei
- 5% Preț: 1035.69 lei
- 5% Preț: 342.13 lei
- 5% Preț: 671.21 lei
- 5% Preț: 345.96 lei
- 5% Preț: 1041.22 lei
- 5% Preț: 1038.44 lei
- 5% Preț: 1216.12 lei
- 5% Preț: 607.64 lei
- 5% Preț: 1042.44 lei
- 5% Preț: 1521.72 lei
- 5% Preț: 1350.30 lei
- 5% Preț: 671.69 lei
- 5% Preț: 672.77 lei
- 5% Preț: 1706.11 lei
- 5% Preț: 1042.10 lei
- 5% Preț: 1340.73 lei
- 5% Preț: 1034.82 lei
- 5% Preț: 678.83 lei
- 5% Preț: 680.41 lei
- 5% Preț: 677.61 lei
- 5% Preț: 1033.75 lei
- 5% Preț: 1035.20 lei
- 5% Preț: 1045.04 lei
- 5% Preț: 1217.84 lei
Preț: 1027.37 lei
Preț vechi: 1081.45 lei
-5% Nou
Puncte Express: 1541
Preț estimativ în valută:
196.65€ • 211.44$ • 163.94£
196.65€ • 211.44$ • 163.94£
Carte tipărită la comandă
Livrare economică 19 decembrie 24 - 02 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783034803182
ISBN-10: 3034803184
Pagini: 120
Ilustrații: X, 110 p.
Dimensiuni: 155 x 235 x 6 mm
Greutate: 0.18 kg
Ediția:2011
Editura: Springer
Colecția Springer
Seria Milestones in Drug Therapy
Locul publicării:Basel, Switzerland
ISBN-10: 3034803184
Pagini: 120
Ilustrații: X, 110 p.
Dimensiuni: 155 x 235 x 6 mm
Greutate: 0.18 kg
Ediția:2011
Editura: Springer
Colecția Springer
Seria Milestones in Drug Therapy
Locul publicării:Basel, Switzerland
Public țintă
ResearchCuprins
Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab – a HER-2 dimerisation inhibitor – for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
Recenzii
From the reviews:
“This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. … It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. … Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing.” (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)
“This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. … It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. … Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing.” (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)
Caracteristici
Contemporary monograph on the treatment of breast cancer.- Gives a comprehensive account of drugs for HER2-positive breast cancer.- A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology Includes supplementary material: sn.pub/extras